TechnicianNational Institute of Allergy and Infectious DiseasesBethesda, Maryland, United States
Disclosure(s): No financial relationships to disclose
593 - Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Saturday, October 19, 20242:00 PM – 2:15 PM US PT